Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia

Overview

Journal Patient Prefer Adherence

Date 2020 Sep 18

PMID 32943851

Citations 6

Authors

Alejandra Caqueo-Urizar

Alfonso Urzua

Patricio Mena-Chamorro

Guillaume Fond

Laurent Boyer

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia.

Methods: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions.

Results: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, = 0.004; self-esteem: β = 0.37, = 0.000; and sentimental life: β = 0.20, = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 -0.56).

Conclusion: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients' QoL in Latin American countries.

Citing Articles

Internalised Stigma, Self-Esteem and Perceived Social Support as Psychosocial Predictors of Quality of Life in Adult Patients with Schizophrenia.

Gagiu C, Dionisie V, Manea M, Mazilu D, Manea M J Clin Med. 2024; 13(22).

PMID: 39598102 PMC: 11594884. DOI: 10.3390/jcm13226959.

Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database.

Pei X, Du X, Liu D, Li X, Wu Y BMJ Open. 2024; 14(11):e087312.

PMID: 39542487 PMC: 11575275. DOI: 10.1136/bmjopen-2024-087312.

Initial attitudes toward a drug predict medication adherence in first-episode patients with schizophrenia: a 1-year prospective study in China.

Dai N, Huang B, Gao T, Zheng Y, Shi C, Pu C BMC Psychiatry. 2023; 23(1):907.

PMID: 38053101 PMC: 10696849. DOI: 10.1186/s12888-023-05419-y.

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia.

Sampogna G, Di Vincenzo M, Giuliani L, Menculini G, Mancuso E, Arsenio E Brain Sci. 2023; 13(11).

PMID: 38002537 PMC: 10669728. DOI: 10.3390/brainsci13111577.

Investigating the Effect of Adherence to Antipsychotic Therapy on the Length of Stay and Number of Hospitalizations in Patients with Schizophrenia - A Descriptive Analysis.

Barliana M, Ramdini D, Afifah N, Alfian S, Sumiwi S Patient Prefer Adherence. 2023; 17:2737-2747.

PMID: 37936717 PMC: 10625877. DOI: 10.2147/PPA.S430083.

References

Boyer L, Aghababian V, Richieri R, Loundou A, Padovani R, Simeoni M . Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 36(2):271-6. DOI: 10.1016/j.pnpbp.2011.10.008. View

Adewuya A, Owoeye O, Erinfolami A, Coker A, Ogun O, Okewole A . Prevalence and correlates of poor medication adherence amongst psychiatric outpatients in southwestern Nigeria. Gen Hosp Psychiatry. 2009; 31(2):167-74. DOI: 10.1016/j.genhosppsych.2008.12.005. View

Nose M, Barbui C, Tansella M . How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003; 33(7):1149-60. DOI: 10.1017/s0033291703008328. View

Medina E, Salva J, Ampudia R, Maurino J, Larumbe J . Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. Patient Prefer Adherence. 2012; 6:623-9. PMC: 3437911. DOI: 10.2147/PPA.S34345. View

Caqueo-Urizar A, Urzua A, Fond G, Boyer L . Medication nonadherence among South American patients with schizophrenia. Patient Prefer Adherence. 2017; 11:1737-1744. PMC: 5640421. DOI: 10.2147/PPA.S144961. View

Puschner B, Angermeyer M, Leese M, Thornicroft G, Schene A, Kikkert M . Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res. 2009; 165(3):224-33. DOI: 10.1016/j.psychres.2007.10.011. View

Adeponle A, Baduku A, Adelekan M, Suleiman G, Adeyemi S . Prospective study of psychiatric follow-up default and medication compliance after discharge at a psychiatric hospital in Nigeria. Community Ment Health J. 2008; 45(1):19-25. DOI: 10.1007/s10597-008-9155-6. View

Andrianarisoa M, Boyer L, Godin O, Brunel L, Bulzacka E, Aouizerate B . Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. Schizophr Res. 2017; 185:173-181. DOI: 10.1016/j.schres.2016.12.021. View

Wang X, Zhang W, Ma N, Guan L, Law S, Yu X . Adherence to Antipsychotic Medication by Community-Based Patients With Schizophrenia in China: A Cross-Sectional Study. Psychiatr Serv. 2016; 67(4):431-7. DOI: 10.1176/appi.ps.201500056. View

10.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

11.

Endriyani L, Chien C, Huang X, Chieh-Yu L . The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia. Perspect Psychiatr Care. 2018; 55(2):147-152. DOI: 10.1111/ppc.12276. View

12.

Hayhurst K, Drake R, Massie J, Dunn G, Barnes T, Jones P . Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2013; 29(3):191-6. DOI: 10.1016/j.eurpsy.2013.03.002. View

13.

Hogan T, Awad A, EASTWOOD R . A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983; 13(1):177-83. DOI: 10.1017/s0033291700050182. View

14.

Ruiz A, Pousa E, Duno R, Crosas J, Cuppa S, Garcia C . [Spanish adaptation of the Scale to Asses Unawareness of Mental Disorder (SUMD)]. Actas Esp Psiquiatr. 2008; 36(2):111-1198. View

15.

Nielsen R, Lindstrom E, Nielsen J, Levander S . DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012; 22(10):747-50. DOI: 10.1016/j.euroneuro.2012.02.008. View

16.

Velligan D, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R . The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70 Suppl 4:1-46. View

17.

Shuler K . Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer Adherence. 2014; 8:701-14. PMC: 4029756. DOI: 10.2147/PPA.S59371. View

18.

Widschwendter C, Kemmler G, Rettenbacher M, Yalcin-Siedentopf N, Hofer A . Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry. 2018; 18(1):212. PMC: 6022409. DOI: 10.1186/s12888-018-1791-y. View

19.

Nitzan U, Bukobza G, Aviram S, Fennig S, Lev-Ran S, Braw Y . Rebelliousness in patients suffering from schizophrenia-spectrum disorders--a possible predictor of attitudes towards medication. Psychiatry Res. 2013; 209(3):297-301. DOI: 10.1016/j.psychres.2012.12.028. View

20.

Robles Garcia R, Salazar Alvarado V, Paez Agraz F, Ramirez Barreto F . [Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish version]. Actas Esp Psiquiatr. 2004; 32(3):138-42. View